Achieve Life Sciences (ACHV) Liabilities and Shareholders Equity (2010 - 2026)

Achieve Life Sciences (ACHV) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $33.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 21.01% year-over-year to $33.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $185.9 million (up 4.01% YoY) and the FY2025 annual result came in at $41.8 million, up 8.17% from the prior year.
• Liabilities and Shareholders Equity fell to $33.1 million in Q1 2026, from $41.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $70.0 million in Q1 2024 to a low of $19.4 million in Q4 2023.
• A 5-year average of $38.6 million and a median of $34.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity jumped 236.71% — and 2025, when it plunged 60.93%.
• Tracing ACHV's Liabilities and Shareholders Equity over 5 years: stood at $30.0 million in 2022, then sank by 35.37% to $19.4 million in 2023, then soared by 99.44% to $38.6 million in 2024, then advanced by 8.17% to $41.8 million in 2025, then fell by 20.78% to $33.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $33.1 million (Q1 2026), $41.8 million (Q4 2025), and $52.0 million (Q3 2025), per Business Quant data.